H.C. Wainwright analyst Yi Chen started Bio-Path Holdings with a Buy rating and $28 price target. The company possesses an "intriguing" technology platform, DNAbilize, consisting of a novel and proprietary way to achieve sustainable systemic delivery of antisense oligonucleotides, Chen tells investors in a research note. Further, the analyst believes prexigebersen could have broad applicability within hematological malignancies as well as solid tumors. Source The fly
Bio-Path Holdings , Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia ( AML ) and chronic myeloid leukemia ( CML ). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX .